JNJ vs. LLY: Johnson & Johnson vs. Eli Lilly Stock Comparison

How do Johnson & Johnson (JNJ) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Johnson & Johnson (JNJ) and Eli Lilly (LLY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Profile ItemJNJLLY
NameJohnson & JohnsonEli Lilly and Company
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization$651.11B$1.2T
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJanuary 2, 1962June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

JNJ
LLY
S&P 500
Loading price history…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Total Return (1Y)36.19%29.90%
Total Return (3Y, Annualized)24.92%31.99%
Total Return (5Y, Annualized)13.81%40.09%

Risk Profile

Drawdown History

JNJ
LLY
S&P 500
Loading price history…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Volatility (1Y, Annualized)21.36%35.39%
Beta (5Y)0.210.43
Max Drawdown (5Y)-18.41%-34.48%
Avg. Volume (3M)7.26M2.59M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
JNJ and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Sharpe Ratio (1Y)1.480.71
Sortino Ratio (1Y)2.261.19

Profitability

ROE (TTM)

Both Johnson & Johnson (JNJ) at 20.02% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
109.18%
JNJ
20.02%
Q3
8.19%
Median
-26.53%
Q1
-61.44%
Min
-151.05%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
8.19%
Median
-26.53%
Q1
-61.44%
Min
-151.05%
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Eli Lilly (LLY) at 31.90% keeps an unusually large share of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share for its industry.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max
18.98%
JNJ
16.20%
Q3
5.73%
Median
0.00%
Q1
-3.30%
Min
-16.57%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
18.98%
Q3
5.73%
Median
0.00%
Q1
-3.30%
Min
-16.57%
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Johnson & Johnson (JNJ) at 26.59% and Eli Lilly (LLY) at 51.25% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.59%

Max
80.14%
JNJ
26.59%
Q3
14.17%
Median
0.00%
Q1
-65.77%
Min
-156.86%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

51.25%

Max
80.14%
LLY
51.25%
Q3
14.17%
Median
0.00%
Q1
-65.77%
Min
-156.86%
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
ROE (TTM)20.02%86.02%
ROA (TTM)8.46%21.06%
Net Margin (TTM)16.20%31.90%
Operating Margin (TTM)26.59%51.25%
Gross Margin (TTM)67.78%83.63%

Growth

Revenue Growth

Both Johnson & Johnson (JNJ) at 6.05% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Johnson & Johnson (JNJ) at 90.50% and Eli Lilly (LLY) at 95.99% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Revenue Growth (YoY)6.05%44.70%
Revenue Growth (3Y CAGR)5.60%31.69%
EPS Growth (YoY)90.50%95.99%
EPS Growth (3Y CAGR)17.90%51.71%

Financial Strength

Current Ratio (MRQ)

Both Johnson & Johnson (JNJ) at 1.02 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max
23.95
Q3
11.13
Median
5.04
Q1
2.43
JNJ
1.02
Min
0.13

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
23.95
Q3
11.13
Median
5.04
Q1
2.43
LLY
1.39
Min
0.13
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.55 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max
1.44
Q3
0.67
JNJ
0.55
Median
0.15
Q1
0.02
Min
0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.44
LLY
1.23
Q3
0.67
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Current Ratio (MRQ)1.021.39
Debt / Equity (MRQ)0.551.23
Net Debt / EBITDA0.790.96

Dividends

Dividend Yield (TTM)

Both Johnson & Johnson (JNJ) at 1.98% and Eli Lilly (LLY) at 0.50% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.98%

JNJ
1.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50%

LLY
0.50%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Johnson & Johnson (JNJ) at 80.12% and Eli Lilly (LLY) at 21.71% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ
80.12%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
Dividend Yield (TTM)1.98%0.50%
Dividend Payout Ratio (TTM)80.12%21.71%

Valuation

P/E Ratio (TTM)

Both Johnson & Johnson (JNJ) at 41.04 and Eli Lilly (LLY) at 43.72 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.04

Max
91.23
Q3
44.74
JNJ
41.04
Median
26.53
Q1
13.26
Min
0.06

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.72

Max
91.23
Q3
44.74
LLY
43.72
Median
26.53
Q1
13.26
Min
0.06
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Johnson & Johnson (JNJ) at 6.55 and Eli Lilly (LLY) at 13.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max
46.64
Q3
20.90
Median
6.79
JNJ
6.55
Q1
3.12
Min
0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.88

Max
46.64
Q3
20.90
LLY
13.88
Median
6.79
Q1
3.12
Min
0.01
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book for their industries: Johnson & Johnson (JNJ) at 7.99 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 29.81 prices above its industry range.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.99

Max
11.93
JNJ
7.99
Q3
6.36
Median
3.19
Q1
1.69
Min
-5.31

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.81

LLY
29.81
Max
11.93
Q3
6.36
Median
3.19
Q1
1.69
Min
-5.31
Loading chart…
Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
MetricJNJLLY
P/E Ratio (TTM)41.0443.72
P/S Ratio (TTM)6.5513.88
P/B Ratio (MRQ)7.9929.81
Free Cash Flow Yield (TTM)2.84%0.78%